New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
07:55 EDTESRX, CVS, CTRXLeerink a buyer of Catamaran ahead of Q2 results
Leerink says it's a buyer of Catamaran (CTRX) ahead of the company's Q2 results as it believes shares have more room to run. The firm is cautious on Express Scripts (ESRX) after hearing from a specialist that service challenges may impact the company's 2015 and 2016 selling seasons. The firm remains positive on CVS Caremark (CVS), but notes shares have outperformed and the company could see retail pressure from recent drug inflation trends.
News For CTRX;ESRX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
09:23 EDTESRXExpress Scripts getting more aggressive on pricing, says Cleveland Research
Subscribe for More Information
October 21, 2014
08:03 EDTCVSCVS offering drug plan with higher co-pay at stores selling tobacco, WSJ says
CVS Health (CVS), which stopped selling tobacco products last month, is now offering a prescription-drug plan via its pharmacy benefits unit Caremark that charges patients copayments that are up to $15 higher on prescriptions filled where tobacco is sold, which includes at rival pharmacies operated by Walgreen (WAG) and Rite-Aid (RAD), reported The Wall Street Journal. Reference Link
October 13, 2014
07:39 EDTESRX, CTRX, CVSPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 9, 2014
09:12 EDTCTRXCatamaran acquisition in-line with expectations, says Leerink
Subscribe for More Information
08:32 EDTCVSCVS Health price target raised to $95 from $87 at Leerink
Subscribe for More Information
07:37 EDTCTRXCatamaran acquisition likely to be well-received, says Oppenheimer
Subscribe for More Information
06:33 EDTCVSCourt considers whether to pay Amazon workers for security checks, WSJ says
Subscribe for More Information
October 8, 2014
16:34 EDTCTRXCatamaran to acquire Salveo Specialty Pharmacy for $260M in cash
Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use